Episurf Medical (EPIS-B)

[Longtrader]

Kommer nok som en kule når det først løsner, best å plukke ferdig under 1,5

[Rahl]

The Swedish patent office PRV has announced its intention to grant another Swedish patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled An implant for cartilage and/or bone repair, is within the area of joint implant materials and implant features.

This is a patent covering combinations of implant bulk and coating materials, to protect specific features of Episurfs Episealer technology. We are happy for this first approval of this patent family, says Katarina Flodström, COO, Episurf Medical.

[Rahl]

Episurf Medical (NASDAQ: EPIS B) has become an approved supplier to BMI Healthcare, the largest independent hospital provider in the UK with 55 hospitals throughout the UK. The decision has been taken following a review process.

We are very pleased that the Episealer, with the support from some of our early customers and leading surgeons in the UK, has received approval from BMI Healthcare as a new treatment method for focal cartilage and bone lesions of the knee, says Pål Ryfors, CEO Episurf Medical. The UK market represents a highly attractive commercial opportunity for us. As we are preparing for further market penetration based on clinical evidence and expanded reimbursement and insurance coverage, it is highly encouraging to be approved as supplier to the largest private hospital group in the UK, concludes Ryfors.

[Sjakk]

Masse positive nyheter, men fortsatt virker det som det er et press for å komme seg ut av en ganske stor posision episurf aksjer.

[Longtrader]

Slutter på oppsiden av 1,5. Heilt greit at den ligger stille mens det lastes aksjer og det fundamentet bygges for oppgang, så kan den gå brått og hardt senere

[Longtrader]

tar en bit til, siste på en stund. så får vi se om der kommer noe rundt siste nyhetene.

[Rahl]

The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled Design method of a rig, is within the area of individualised surgical instruments related to the companys Episealer implants.

This patent covers parts of the surgical instruments that, together with the individualised Episealer implants and Episurfs imaging technology, form the Episealer technology, says Katarina Flodström, COO, Episurf Medical.

[Buffet]

Det er virkelig en seig aksje dette er. Men tålmodighet lønner seg nok her omsider

[Rahl]

Den er seig ja. Men har godt inntrykk av ledelsen og gjennomføring. Og selvfølgelig et supert inntrykk av produktet. Holder denne til the bitter end.

[Rahl]

[Pl Ryfors CEO Episurf Medical]

Despite this very challenging business climate, Episurf has taken some significant and critical steps during the quarter. The number of orders for Episealer implants exceeded the corresponding quarter previous year. This was an exceptionally strong achievement in what are the most challenging market conditions in living memory, patient recruitment in the pivotal clinical trial in the US was initiated, the first surgeries since the CE-clearance of our ankle implant Episealer Talus were performed, the first surgery in Asia was planned, and the results from the largest European multi-center study for the Episealer knee implant were submitted to a scientific journal for publication, reporting on strong clinical outcomes. All of this at the same time as the expenses were significantly lower compared to the second quarter last year says Pål Ryfors, CEO Episurf Medical.

Second quarter 2020 compared to 2019, Group

• Gross order intake amounted to SEK 1.0m (1.3), a decrease of 22%. We experienced a 2% increase in orders for Episealer implants during the quarter with 50 (49) approved orders

• Order backlog amounted to SEK 1.2m (0.7), an increase of 60%

• Group net sales decreased by 46% to SEK 0.6m (1.1), as a result of the halting of elective surgeries in Europe due to Covid-19

• Loss for the period amounted to SEK -14.4m (-18.9); the decreased costs during the quarter are primarily due to SEK 1.9m lower cost for the US and cost savings in connection with Covid-19

• Earnings per share amounted to SEK -0.08 (-0.42)

First six months 2020 compared to first six months 2019, Group

• Gross order intake amounted to SEK 2.5m (2.5) a decrease of 1%

• 21% increase in orders for Episealer implants during the first six months with 119 (98) approved orders

• Group net sales decreased by 18% to SEK 2.1m (2.5) during the first six months

• Loss for the period amounted to SEK -32.3m (-33.5)

• Earnings per share amounted to SEK -0.24 (0.77)

Significant events during the second quarter

• Episurf Medical announced that results from Episealer Knee multicenter study have been submitted

• Episurf Medical has received patent approvals in Europe, Korea, Japan, and Sweden

• Episurf Medical announced that the first surgery in the Asia-Pacific region has been scheduled

• Episurf Medical announced that enrolment of patients has been initiated in North America and Europe in Episurf Medicals IDE clinical trial

• Episurf Medical conducted a rights issue and raised approximately SEK 51m before to transaction costs (as part of a larger transaction of SEK 141m)

Significant events after the second quarter

• Episurf Medical has become an approved supplier to BMI Healthcare, the largest hospital provider in the UK

• Episurf Medical has received patent approval in Europe

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

[holmes]

EPISURF

Episurfs vd ökar innehavet något (Finwire)

2020-07-17 09:38

Medicinteknikbolaget Episurf Medicals vd Pål Ryfors ökar innehavet något. Idag, den 17 juni, köpte vd:n 17 800 aktier till kursen 1,47 kronor per aktie. Köpesumman uppgår till 26 202 kronor. Det framgår av Finansinspektionens insynsregister.

Carl Becht
carl.becht@finwire.se
Nyhetsbyrån Finwire

[Savepig]

Kneoperasjoner står vel høyt på lista over ting som ble nedprioritert i Q2

[Rahl]

As we expected, Covid-19 had a clear impact on the number of implant procedures in Q2. As these are elective procedures, they can easily be postponed (as seen in Q2). Despite this, we believe the company had a strong quarter with a good cost control. Over the coming quarters, we believe sales should gradually return. Our new fair value is SEK1.3-3.9 (1.4-4.1).

The pandemic affected Q2, as we expected. Sales of cSEK0.6m were clearly below our estimate of cSEK1m. However, as the company is in the early phase of its product introduction, it has few high-volume users and local restrictions can have a disproportionately high impact on a company at its stage of development. The signs are positive that the important European market is starting to come back.

Tight cost control in Q2. Despite lower than expected sales, the company reduced its operating costs, giving an operating loss cSEK4m smaller than we forecast. On the other hand, we expect costs to increase again in H2 as costs for the US IDE trial grow as surgical procedures in the trial commences.

At least two publications should come in H2. We expect clinical documentation to increase in H2, as several important articles highlighting the longer-term outcomes for the Episealer implant system are on their way. Remember that the company has basically come this far with very limited clinical documentation, and from our point of view it is key to strengthening its competitive situation.

Forecasts adjusted for Q2 report. We have lowered our forecasts due to the impact of Covid-19 in Q2 and the impact we expect for H2. At the same time as we have lowered our 2020-2022e top-line and our operating costs, leading to a relatively small bottom-line impact. We still see high demand for its implant system in patients too old for any biological treatment to have an effect and too young for total knee replacements. Our new fair value is SEK1.3-3.9 (previously SEK1.4-4.1).

Click here to view full report (https://www.dnb.no/seg-fundamental/fundamentalweb/GetReports.aspx?file=CMPSP_159592.pdf&Sid=1-7XT0MIJ)

Best regards

---

Patrik Ling | DNB Markets | Equity Research | Senior Analyst Healthcare

DNB Bank ASA

[Rahl]

Slow and steady.

Episurf Medical (Nasdaq: EPIS B) today announces that a surgery with the knee implant Episealer has been scheduled to take place in Poland in the coming weeks.

We are now adding Poland to the markets where surgeries with the Episealer implant are performed. Adding to the history, one of the first Episealer surgeries ever took lace in Poland, but this is the first one since we decided to continue our expansion on the back of strong clinical performance. In addition to Poland, we have added Italy and Asia during 2020, reflecting the fact that we are executing on our strategy. We have recently appointed an individual as Head of Distribution markets, and we are continuing our global launch, at the same time as the clinical programs are running well says Pål Ryfors, CEO Episurf Medical.

[holmes]

Godkjent dag for Episurf, kanskje startskuddet for noe stort?

[Savepig]

Litt til trengs for å sette to streker under svaret, men pen move

[holmes]

EPISURF

Episurfs vd Pål Ryfors ökar aktieinnehavet något (Finwire)

2020-08-13 10:35

Medicinteknikbolaget Episurf Medicals vd Pål Ryfors har den 13 augusti köpt 50 000 B-aktier i bolaget. Aktierna köptes till kursen 1,51 kronor per aktie, en affär på 75 000 kronor. Affären gjordes på Nasdaq Stockholm. Det framgår av Finansinspektionens insynsregister.

Henrik Öhlin
henrik.ohlin@finwire.se, 0703-21 06 99
Nyhetsbyrån Finwire

[Savepig]

Kjører han buss på kveldene for å få råd til alle aksjene egentlig?

[holmes]

På tide for oss tålmodige lutrede Episurf aksjonærer å få betalt for ventingen

[Buffet]

Da var jeg ihvertfall break-even om ikke annet. Får krysse fingrene for at det fortsetter i denne triste aksjen!